PRODUCT INFORMATION

TRX-818 (sodium salt)

Item No. 22209

CAS Registry No.:	1256037-62-3
Formal Name:	2-(3-fluorophenyl)-6-methoxy-5-(phosphonooxy)-4(1H)-quinolinone, disodium salt
MF:	$C_{16}H_{11}FNO_6P$ • 2Na
FW:	409.2
Purity:	≥98%
UV/Vis.:	λ_{max}: 271, 356 nm
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

TRX-818 (sodium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the TRX-818 (sodium salt) in the solvent of choice, which should be purged with an inert gas. TRX-818 (sodium salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of TRX-818 (sodium salt) in ethanol is approximately 1 mg/ml and approximately 10 mg/ml in DMSO and DMF.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of TRX-818 (sodium salt) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of TRX-818 (sodium salt) in PBS, pH 7.2, is approximately 0.5 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

TRX-818 is an anticancer compound.[1,2] It inhibits vasculogenic mimicry network formation in C8161 and SK-MEL-28 melanoma cells when used at concentrations ranging from less than or equal to 5 to 10 nM.[1] TRX-818 (10 nM) decreases pro-Nodal protein levels and Smad2 phosphorylation in C8161 cells. It reduces tumor volume with a minimum effective dose (MED) value of 50 mg/kg and decreases the number of vasculogenic mimicry channels in tumors when administered at a dose of 100 mg/kg in an HCT116 colon cancer mouse xenograft model. TRX-818 (7.5, 15, and 30 mg/kg) reduces tumor growth in a Hep3B mouse xenograft model in a dose-dependent manner.[2]

References

1. Chu, Y.-W. and Chien, D.-S. Use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry. *Tairx Inc.* **US009717721B2** (2016).
2. Chou, L.-C., Tsai, M.-T., Hsu, M.-H., *et al.* Design, synthesis, and preclinical evaluation of new 5,6- (or 6,7-) disubstituted-2-(fluorophenyl)quinolin-4-one derivatives as potent antitumor agents. *J. Med. Chem.* **53(22)**, 8047-8058 (2010).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM